The subcutaneous formulation of daratumumab makes treatment a faster and more tolerable process for patients with multiple myeloma.

The subcutaneous formulation of daratumumab makes treatment a faster and more tolerable process for patients with multiple ...

The FDA has approved a ready-to-dilute, multi-dose formulation of thiotepa (Tepylute) for use in breast and ovarian adenocarcinomas, according to a news release on April 29 from Shorla Oncology, the ...

Panelists discuss how patient education plays a crucial role in ensuring adherence to tyrosine kinase inhibitor (TKI) therapy by building trust through clear explanations of medications and expected ...

Panelists discuss how establishing trust and open communication with patients with chronic myeloid leukemia (CML) is crucial for treatment adherence, emphasizing the importance of asking specific ...

The selective CDK2 inhibitor INX-315 has been given FDA fast track designation for use in CCNE1-amplified, platinum-resistant ...

Oncology nurses can encourage clinical trial enrollment for patients with anaplastic thyroid cancer, a rare and aggressive ...

The FDA has approved a ready-to-dilute, multi-dose formulation of thiotepa (Tepylute) for use in breast and ovarian ...

Cilta-Cel Improves QOL, Extends Treatment Breaks vs SOC in R/R Myeloma ...

Nurse practitioners and physician assistants can advocate to play a number of roles in oncology research, including primary ...

AYA Cancer Awareness month offers an opportunity for nurses to go further in supporting AYAs with cancer.